| Product NDC: | 0173-0565 |
| Proprietary Name: | VALTREX |
| Non Proprietary Name: | valacyclovir hydrochloride |
| Active Ingredient(s): | 1 g/1 & nbsp; valacyclovir hydrochloride |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, FILM COATED |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0173-0565 |
| Labeler Name: | GlaxoSmithKline LLC |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA020487 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20020812 |
| Package NDC: | 0173-0565-10 |
| Package Description: | 90 TABLET, FILM COATED in 1 BOTTLE (0173-0565-10) |
| NDC Code | 0173-0565-10 |
| Proprietary Name | VALTREX |
| Package Description | 90 TABLET, FILM COATED in 1 BOTTLE (0173-0565-10) |
| Product NDC | 0173-0565 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | valacyclovir hydrochloride |
| Dosage Form Name | TABLET, FILM COATED |
| Route Name | ORAL |
| Start Marketing Date | 20020812 |
| Marketing Category Name | NDA |
| Labeler Name | GlaxoSmithKline LLC |
| Substance Name | VALACYCLOVIR HYDROCHLORIDE |
| Strength Number | 1 |
| Strength Unit | g/1 |
| Pharmaceutical Classes | DNA Polymerase Inhibitors [MoA],Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient] |